References

Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial

10.1001/jama.2016.11136 · ExternalCitation · doi-reference

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial

10.1001/jama.282.7.637 · ExternalCitation · doi-reference

Prodrug strategies in anticancer chemotherapy

10.1002/cmdc.200700159 · ExternalCitation · doi-reference

Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody

10.1002/jbmr.173 · ExternalCitation · doi-reference

The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years

10.1002/jbmr.1768 · ExternalCitation · doi-reference

Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research

10.1002/jbmr.1998 · ExternalCitation · doi-reference

Osthole stimulates osteoblast differentiation and bone formation by activation of beta-catenin–BMP signaling

10.1002/jbmr.21 · ExternalCitation · doi-reference

A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density

10.1002/jbmr.2351 · ExternalCitation · doi-reference

Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus

10.1002/jbmr.2405 · ExternalCitation · doi-reference

Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis

10.1002/jbmr.3051 · ExternalCitation · doi-reference

BPS804 anti-sclerostin antibody in adults with moderate osteogenesis imperfecta: results of a randomized phase 2a trial

10.1002/jbmr.3143 · ExternalCitation · doi-reference

The amazing osteocyte

10.1002/jbmr.320 · ExternalCitation · doi-reference

Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension

10.1002/jbmr.3337 · ExternalCitation · doi-reference

Change in bone density and reduction in fracture risk: a meta-regression of published trials

10.1002/jbmr.3641 · ExternalCitation · doi-reference

The diagnosis of osteoporosis

10.1002/jbmr.5650090802 · ExternalCitation · doi-reference

Genistein stimulates the osteoblastic differentiation via NO/cGMP in bone marrow culture

10.1002/jcb.20308 · ExternalCitation · doi-reference

Regulation of osteoblast differentiation by transcription factors

10.1002/jcb.20958 · ExternalCitation · doi-reference

Multiple-dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA-IgG1), a novel erythropoietic agent, in healthy postmenopausal women

10.1002/jcph.160 · ExternalCitation · doi-reference

The role of traditional Chinese medicines in osteogenesis and angiogenesis

10.1002/ptr.4959 · ExternalCitation · doi-reference

Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates

10.1006/bbrc.1999.1499 · ExternalCitation · doi-reference

Tetracycline-based histological analysis of bone remodeling

10.1007/bf02058664 · ExternalCitation · doi-reference

An estimate of the worldwide prevalence and disability associated with osteoporotic fractures

10.1007/s00198-006-0172-4 · ExternalCitation · doi-reference

Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy

10.1007/s00198-007-0540-8 · ExternalCitation · doi-reference

Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards

10.1007/s00198-010-1501-1 · ExternalCitation · doi-reference

Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the ESCEO and IOF

10.1007/s00198-019-05104-5 · ExternalCitation · doi-reference

Explanations for the difference in rates of cardiovascular events in a trial of alendronate and romosozumab

10.1007/s00198-020-05379-z · ExternalCitation · doi-reference

Calcimimetic and calcilytic drugs: feats, flops, and futures

10.1007/s00223-015-0052-z · ExternalCitation · doi-reference

Exploring the osteogenic potential of semisynthetic triterpenes from Combretum leprosum: an in vitro and in silico study

10.1007/s11626-024-00928-w · ExternalCitation · doi-reference

The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial

10.1007/s13539-011-0034-6 · ExternalCitation · doi-reference

Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice

10.1016/0092-8674(91)90499-o · ExternalCitation · doi-reference

Icariin inhibits RANKL-induced osteoclastogenesis via modulation of the NF-κB and MAPK signaling pathways

10.1016/j.bbrc.2018.11.201 · ExternalCitation · doi-reference

A bone-targeted engineered exosome platform delivering siRNA to treat osteoporosis

10.1016/j.bioactmat.2021.09.015 · ExternalCitation · doi-reference

Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases

10.1016/j.biocel.2008.06.010 · ExternalCitation · doi-reference

Effect of naringin collagen graft on bone formation

10.1016/j.biomaterials.2005.11.009 · ExternalCitation · doi-reference

A delivery system specifically approaching bone resorption surfaces to facilitate therapeutic modulation of microRNAs in osteoclasts

10.1016/j.biomaterials.2015.02.007 · ExternalCitation · doi-reference

Icariin promotes osteogenic differentiation of rat bone marrow stromal cells by activating the ERα-Wnt/β-catenin signaling pathway

10.1016/j.biopha.2016.09.107 · ExternalCitation · doi-reference

Bisphosphonates: the first 40 years

10.1016/j.bone.2011.04.022 · ExternalCitation · doi-reference

Bisphosphonates in cancer therapy

10.1016/j.canlet.2007.07.007 · ExternalCitation · doi-reference

Proteolysis-targeting chimeras as therapeutics and tools for biological discovery

10.1016/j.cell.2019.11.031 · ExternalCitation · doi-reference

Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis

10.1016/j.cmet.2006.05.012 · ExternalCitation · doi-reference

Targeting the Wnt/beta-catenin pathway in cancer: update on effectors and inhibitors

10.1016/j.ctrv.2017.11.002 · ExternalCitation · doi-reference

Fisetin is a senotherapeutic that extends health and lifespan

10.1016/j.ebiom.2018.09.015 · ExternalCitation · doi-reference

Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease

10.1016/j.ebiom.2019.08.069 · ExternalCitation · doi-reference

Development of controlled drug delivery systems for bone fracture-targeted therapeutic delivery: a review

10.1016/j.ejpb.2018.02.023 · ExternalCitation · doi-reference

Integrating metabolomics and network pharmacology to study the mechanism of Er-Xian decoction in improving intervertebral disc degeneration

10.1016/j.jep.2025.119702 · ExternalCitation · doi-reference

Fracture prediction and the definition of osteoporosis in children and adolescents: the ISCD 2013 pediatric official positions

10.1016/j.jocd.2014.01.004 · ExternalCitation · doi-reference

An overview of current and emerging SERMs

10.1016/j.jsbmb.2014.03.003 · ExternalCitation · doi-reference

Flavonoids of Herba Epimedii regulate osteogenesis of human mesenchymal stem cells through BMP and Wnt/beta-catenin signaling pathway

10.1016/j.mce.2009.08.012 · ExternalCitation · doi-reference

Spatiotemporal complexity and druggability of PTH1R: insights from small molecules and peptides

10.1016/j.mce.2026.112814 · ExternalCitation · doi-reference

Osteotropic nanoscale drug delivery systems based on small molecule bone-targeting moieties

10.1016/j.nano.2016.08.015 · ExternalCitation · doi-reference

Green tea and bone metabolism

10.1016/j.nutres.2009.06.008 · ExternalCitation · doi-reference

Osteogenic effects of flavonoid aglycones from an osteoprotective fraction of Drynaria fortunei — an in vitro efficacy study

10.1016/j.phymed.2011.01.022 · ExternalCitation · doi-reference

Selective androgen receptor modulators: current knowledge and clinical applications

10.1016/j.sxmr.2018.09.006 · ExternalCitation · doi-reference

What old means to bone

10.1016/j.tem.2010.01.010 · ExternalCitation · doi-reference

Estrogen and the skeleton

10.1016/j.tem.2012.03.008 · ExternalCitation · doi-reference

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

10.1016/s0092-8674(00)81569-x · ExternalCitation · doi-reference

Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man

10.1016/s0092-8674(01)00206-9 · ExternalCitation · doi-reference

Osteoporosis: now and the future

10.1016/s0140-6736(10)62349-5 · ExternalCitation · doi-reference

Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial

10.1016/s0140-6736(13)60856-9 · ExternalCitation · doi-reference

Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial

10.1016/s0140-6736(15)61120-5 · ExternalCitation · doi-reference

Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial

10.1016/s0140-6736(17)31613-6 · ExternalCitation · doi-reference

Osteoporosis

10.1016/s0140-6736(18)32112-3 · ExternalCitation · doi-reference

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture intervention trial research group

10.1016/s0140-6736(96)07088-2 · ExternalCitation · doi-reference

10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension

10.1016/s2213-8587(17)30138-9 · ExternalCitation · doi-reference

Use of bone turnover markers in postmenopausal osteoporosis

10.1016/s2213-8587(17)30184-5 · ExternalCitation · doi-reference

Osteoporosis treatment: recent developments and ongoing challenges

10.1016/s2213-8587(17)30188-2 · ExternalCitation · doi-reference

Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study

10.1016/s2213-8587(19)30346-8 · ExternalCitation · doi-reference

Targeted and nontargeted bone remodeling: relationship to basic multicellular unit origination and progression

10.1016/s8756-3282(01)00642-1 · ExternalCitation · doi-reference

Linking bisphosphonates to the free amino groups in fluoroquinolones: preparation of osteotropic prodrugs for the prevention and treatment of osteomyelitis

10.1021/jm801007z · ExternalCitation · doi-reference

Bioavailability of curcumin: problems and promises

10.1021/mp700113r · ExternalCitation · doi-reference

Osteogenic effects of D+beta-3,4-dihydroxyphenyl lactic acid (salvianic acid A, SAA) on osteoblasts and bone marrow stromal cells of intact and prednisone-treated rats

10.1038/aps.2009.9 · ExternalCitation · doi-reference

The Hedgehog signalling pathway in bone formation

10.1038/ijos.2015.14 · ExternalCitation · doi-reference

Osteoclast differentiation and activation

10.1038/nature01658 · ExternalCitation · doi-reference

Osteoprotection by semaphorin 3A

10.1038/nature11000 · ExternalCitation · doi-reference

Network pharmacology: the next paradigm in drug discovery

10.1038/nchembio.118 · ExternalCitation · doi-reference

A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair

10.1038/ncomms11505 · ExternalCitation · doi-reference

Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture

10.1038/ng.2249 · ExternalCitation · doi-reference

Evidence for osteocyte regulation of bone homeostasis through RANKL expression

10.1038/nm.2452 · ExternalCitation · doi-reference

A delivery system targeting bone formation surfaces to facilitate RNAi-based anabolic therapy

10.1038/nm.2617 · ExternalCitation · doi-reference

miR-214 targets ATF4 to inhibit bone formation

10.1038/nm.3026 · ExternalCitation · doi-reference

WNT signaling in bone homeostasis and disease: from human mutations to treatments

10.1038/nm.3074 · ExternalCitation · doi-reference

LGR4 is a receptor for RANKL and negatively regulates osteoclast differentiation and bone resorption

10.1038/nm.4076 · ExternalCitation · doi-reference

Targeting cellular senescence prevents age-related bone loss in mice

10.1038/nm.4385 · ExternalCitation · doi-reference

Merck &Co. drops osteoporosis drug odanacatib

10.1038/nrd.2016.207 · ExternalCitation · doi-reference

Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab

10.1038/nrd3705 · ExternalCitation · doi-reference

Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems

10.1038/nri2062 · ExternalCitation · doi-reference

Identification of HSP90 inhibitors as a novel class of senolytics

10.1038/s41467-017-00314-z · ExternalCitation · doi-reference

PROTAC targeted protein degraders: the past is prologue

10.1038/s41573-021-00371-6 · ExternalCitation · doi-reference

Extracellular targeted protein degradation: an emerging modality for drug discovery

10.1038/s41573-023-00833-z · ExternalCitation · doi-reference

Highly accurate protein structure prediction with AlphaFold

10.1038/s41586-021-03819-2 · ExternalCitation · doi-reference

A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity

10.1038/s41591-019-0668-z · ExternalCitation · doi-reference

Cathepsin K inhibitors: a novel target for osteoporosis therapy

10.1038/sj.clpt.6100450 · ExternalCitation · doi-reference

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

10.1056/nejm200105103441904 · ExternalCitation · doi-reference

Postmenopausal osteoporosis

10.1056/nejmcp1513724 · ExternalCitation · doi-reference

High bone density due to a mutation in LDL-receptor-related protein 5

10.1056/nejmoa013444 · ExternalCitation · doi-reference

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma

10.1056/nejmoa030847 · ExternalCitation · doi-reference

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis

10.1056/nejmoa031975 · ExternalCitation · doi-reference

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

10.1056/nejmoa067312 · ExternalCitation · doi-reference

Lasofoxifene in postmenopausal women with osteoporosis

10.1056/nejmoa0808692 · ExternalCitation · doi-reference

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

10.1056/nejmoa0809493 · ExternalCitation · doi-reference

Romosozumab in postmenopausal women with low bone mineral density

10.1056/nejmoa1305224 · ExternalCitation · doi-reference

Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor

10.1056/nejmoa1411366 · ExternalCitation · doi-reference

Romosozumab treatment in postmenopausal women with osteoporosis

10.1056/nejmoa1607948 · ExternalCitation · doi-reference

Romosozumab or alendronate for fracture prevention in women with osteoporosis

10.1056/nejmoa1708322 · ExternalCitation · doi-reference

Burosumab therapy in children with X-linked hypophosphatemia

10.1056/nejmoa1714641 · ExternalCitation · doi-reference

A phase 3 trial of luspatercept in patients with transfusion-dependent β-thalassemia

10.1056/nejmoa1910182 · ExternalCitation · doi-reference

Bisphosphonates for osteoporosis — where do we go from here?

10.1056/nejmp1202619 · ExternalCitation · doi-reference

A soluble activin type IIA receptor induces bone formation and improves skeletal integrity

10.1073/pnas.0711263105 · ExternalCitation · doi-reference

Regulation of myostatin activity and muscle growth

10.1073/pnas.151270098 · ExternalCitation · doi-reference

Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice

10.1073/pnas.95.23.13453 · ExternalCitation · doi-reference

Reconstitution of a frizzled8·Wnt3a·LRP6 signaling complex reveals multiple Wnt and Dkk1 binding sites on LRP6

10.1074/jbc.m109.092130 · ExternalCitation · doi-reference

Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling

10.1074/jbc.m413274200 · ExternalCitation · doi-reference

Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety

10.1080/01926230252929882 · ExternalCitation · doi-reference

Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)

10.1093/hmg/10.5.537 · ExternalCitation · doi-reference

Population-based study of survival after osteoporotic fractures

10.1093/oxfordjournals.aje.a116756 · ExternalCitation · doi-reference

Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease

10.1101/gr.3437105 · ExternalCitation · doi-reference

The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs

10.1111/acel.12344 · ExternalCitation · doi-reference

A phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events

10.1111/bjh.13056 · ExternalCitation · doi-reference

Calcimimetic and calcilytic therapies for inherited disorders of the calcium-sensing receptor signalling pathway

10.1111/bph.14086 · ExternalCitation · doi-reference

Senolytic drugs: from discovery to translation

10.1111/joim.13141 · ExternalCitation · doi-reference

Osteogenic effects of resveratrol in vitro: potential for the prevention and treatment of osteoporosis

10.1111/nyas.12145 · ExternalCitation · doi-reference

Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl

10.1124/jpet.103.057273 · ExternalCitation · doi-reference

Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease

10.1124/pr.111.004846 · ExternalCitation · doi-reference

Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency

10.1126/science.273.5279.1236 · ExternalCitation · doi-reference

Structure and dynamics of the active human parathyroid hormone receptor-1

10.1126/science.aav7942 · ExternalCitation · doi-reference

Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics

10.1126/scitranslmed.aay6570 · ExternalCitation · doi-reference

Pterostilbene on metabolic parameters: a randomized, double-blind, and placebo-controlled trial

10.1155/2014/459165 · ExternalCitation · doi-reference

A peptidomimetic antagonist of the alpha(v)beta3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo

10.1172/jci119404 · ExternalCitation · doi-reference

Regulation of bone mass by Wnt signaling

10.1172/jci28551 · ExternalCitation · doi-reference

Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone

10.1172/jci6610 · ExternalCitation · doi-reference

Pharmacodynamic effects on biochemical markers of bone turnover and pharmacokinetics of the cathepsin K inhibitor ONO-5334 in an ascending multiple-dose, phase 1 study

10.1177/0091270011399080 · ExternalCitation · doi-reference

The selective cathepsin K inhibitor MIV-711 attenuates joint pathology in experimental animal models of osteoarthritis

10.1186/s12967-018-1425-7 · ExternalCitation · doi-reference

Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling

10.1210/en.2015-1726 · ExternalCitation · doi-reference

Effect of L-000845704, an alphaVbeta3 integrin antagonist, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women

10.1210/jc.2004-2126 · ExternalCitation · doi-reference

In vivo assessment of trabecular bone microarchitecture by high-resolution peripheral quantitative computed tomography

10.1210/jc.2005-1258 · ExternalCitation · doi-reference

Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial

10.1210/jc.2013-1707 · ExternalCitation · doi-reference

A phase 2, randomized, placebo-controlled, dose-ranging study of the calcium-sensing receptor antagonist MK-5442 in the treatment of postmenopausal women with osteoporosis

10.1210/jc.2013-4009 · ExternalCitation · doi-reference

Two years of denosumab and teriparatide administration in postmenopausal women with osteoporosis (the DATA Extension Study): a randomized controlled trial

10.1210/jc.2013-4440 · ExternalCitation · doi-reference

Resveratrol increases bone mineral density and bone alkaline phosphatase in obese men: a randomized placebo-controlled trial

10.1210/jc.2014-2799 · ExternalCitation · doi-reference

Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025

10.1359/jbmr.061113 · ExternalCitation · doi-reference

Review of nonprimate, large animal models for osteoporosis research

10.1359/jbmr.080516 · ExternalCitation · doi-reference

Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL

10.1359/jbmr.081112 · ExternalCitation · doi-reference

Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trial

10.1359/jbmr.090830 · ExternalCitation · doi-reference

Cathepsin K inhibitors for osteoporosis and potential off-target effects

10.1517/13543780902832661 · ExternalCitation · doi-reference

Bone-specific drug delivery systems: approaches via chemical modification of bone-seeking agents

10.2165/00003088-200342150-00002 · ExternalCitation · doi-reference

Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy

10.3109/13697137.2013.834493 · ExternalCitation · doi-reference

Quercetin as an agent for protecting the bone: a review of the current evidence

10.3390/ijms21176448 · ExternalCitation · doi-reference

(-)-Epigallocatechin-3-gallate (EGCG) enhances osteogenic differentiation of human bone marrow mesenchymal stem cells

10.3390/molecules23123221 · ExternalCitation · doi-reference

Icaritin, a novel plant-derived osteoinductive agent, enhances the osteogenic differentiation of human bone marrow- and human adipose tissue-derived mesenchymal stem cells

10.3892/ijmm.2017.2906 · ExternalCitation · doi-reference

Ginseng saponins and the treatment of osteoporosis: mini literature review

10.5142/jgr.2013.37.261 · ExternalCitation · doi-reference

Effects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women: a randomized trial

10.7326/0003-4819-146-12-200706190-00005 · ExternalCitation · doi-reference

Disease-modifying effects of a novel cathepsin K inhibitor in osteoarthritis: a randomized controlled trial

10.7326/m19-0675 · ExternalCitation · doi-reference